中华胸心血管外科杂志
中華胸心血管外科雜誌
중화흉심혈관외과잡지
Chinese Journal of Thoracic and Cardiovascular Surgery
2013年
3期
156-160
,共5页
王伟%宋伟安%路平%李军%胡艳正%尚立群%李学昌%文锋%刘军强
王偉%宋偉安%路平%李軍%鬍豔正%尚立群%李學昌%文鋒%劉軍彊
왕위%송위안%로평%리군%호염정%상립군%리학창%문봉%류군강
癌,非小细胞肺%ERCC1%RRM1%预后%无病生存%无疾病进展时间
癌,非小細胞肺%ERCC1%RRM1%預後%無病生存%無疾病進展時間
암,비소세포폐%ERCC1%RRM1%예후%무병생존%무질병진전시간
Carcinoma,non-small cell lung%ERCC1%RRM1%Prognosis%Disease-free surviul%Progressive free survival
目的 探讨非小细胞肺癌完全切除术后ERCC1、RRM1的表达与预后的关系.方法 86例NSCLC手术后标本中肿瘤组织应用免疫组织化学方法进行ERCC1、RRM1蛋白表达检测.回顾性分析NSCLC患者的临床特征、生存期与肿瘤组织中ERCC1、RRM1蛋白表达的关系.结果 86例手术根治性切除NSCLC组织中ERCC1、RRM1蛋白表达阳性率分别为41.9％、36.1％.ERCC1和RRM1蛋白表达阳性率与患者的性别、年龄、吸烟状况、淋巴结转移情况、组织学类型及临床分期均无明显相关性(P＞0.05).ERCC1蛋白表达阳性患者的无疾病进展时间(28.5个月)和1、2年生存率(94.3％、62.6％)与阴性患者(30.0个月,94.3％、71.4％)差异均无统计学意义(P＞0.05).RRM1蛋白表达阳性患者的无疾病进展时间(25.0个月)和1、2年生存率(86.6％、55.8％)低于RRM1蛋白表达阴性患者(31.2个月,98.2％、65.1％),差异有统计学意义(P＜0.05).结论 可完全切除NSCLC的患者预后与肿瘤组织中RRM1蛋白表达相关.
目的 探討非小細胞肺癌完全切除術後ERCC1、RRM1的錶達與預後的關繫.方法 86例NSCLC手術後標本中腫瘤組織應用免疫組織化學方法進行ERCC1、RRM1蛋白錶達檢測.迴顧性分析NSCLC患者的臨床特徵、生存期與腫瘤組織中ERCC1、RRM1蛋白錶達的關繫.結果 86例手術根治性切除NSCLC組織中ERCC1、RRM1蛋白錶達暘性率分彆為41.9％、36.1％.ERCC1和RRM1蛋白錶達暘性率與患者的性彆、年齡、吸煙狀況、淋巴結轉移情況、組織學類型及臨床分期均無明顯相關性(P＞0.05).ERCC1蛋白錶達暘性患者的無疾病進展時間(28.5箇月)和1、2年生存率(94.3％、62.6％)與陰性患者(30.0箇月,94.3％、71.4％)差異均無統計學意義(P＞0.05).RRM1蛋白錶達暘性患者的無疾病進展時間(25.0箇月)和1、2年生存率(86.6％、55.8％)低于RRM1蛋白錶達陰性患者(31.2箇月,98.2％、65.1％),差異有統計學意義(P＜0.05).結論 可完全切除NSCLC的患者預後與腫瘤組織中RRM1蛋白錶達相關.
목적 탐토비소세포폐암완전절제술후ERCC1、RRM1적표체여예후적관계.방법 86례NSCLC수술후표본중종류조직응용면역조직화학방법진행ERCC1、RRM1단백표체검측.회고성분석NSCLC환자적림상특정、생존기여종류조직중ERCC1、RRM1단백표체적관계.결과 86례수술근치성절제NSCLC조직중ERCC1、RRM1단백표체양성솔분별위41.9％、36.1％.ERCC1화RRM1단백표체양성솔여환자적성별、년령、흡연상황、림파결전이정황、조직학류형급림상분기균무명현상관성(P＞0.05).ERCC1단백표체양성환자적무질병진전시간(28.5개월)화1、2년생존솔(94.3％、62.6％)여음성환자(30.0개월,94.3％、71.4％)차이균무통계학의의(P＞0.05).RRM1단백표체양성환자적무질병진전시간(25.0개월)화1、2년생존솔(86.6％、55.8％)저우RRM1단백표체음성환자(31.2개월,98.2％、65.1％),차이유통계학의의(P＜0.05).결론 가완전절제NSCLC적환자예후여종류조직중RRM1단백표체상관.
Objective To explore the relationship between the expression of ERCC1,RRM1 and the clinical prognosis in operable non-small cell lung cancer (NSCLC) patients.Methods The expression of ERCC1 and RRM1 protein in 86 cases was detected by immunohistochemical methods.The relationship between the expression of ERCC1 and RRM1 protein and the clinical characteristics,postoperative survival were analyzed retrospectively.Results The positive expression of ERCC1,RRM1 protein in 86 cases was 47.5％,35.2％,respectively.There was no significant correlation between the positive expression of ERCC1 and RRM1 protein and gender,age,smoking status,lymph node metastasis,histological types and clinical staging (P ＞ 0.05).There was no significant difference in progressive free survival (PFS) and 1-,2-year survival rate between ERCClpositive group (28.5 months,94.3 ％,62.6％) and ERCC 1 negative group (30.0 months,94.3 ％,71.4％),P ＞0.05.Patients with positive expression of RRM1 protein had a lower PFS and 1-,2-year survival rate (25.0 months,86.6％,55.8％) than those with negative expression of RRM1 protein (31.2 months,98.2％,65.1％),P ＜ 0.05.Conclusion The expression of RRM1 protein in cancer tissues is closely related to the clinical prognostic and survival status in operable NSCLC patients.
